跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NL-OMON36211
NL-OMON36211撤回2 期

Cisplatin or Cetuximab and conventional versus redistributed radiation for advanced head and neck cancer - ARTFORCE

ederlands Kanker Instituut0 个研究点目标入组 0 人开始时间: 待定最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
2 期
状态
撤回
发起方
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99（—）

入选标准

  • •Stage III-IV T3-4 SCC Head and Neck, Oropharynx, Oral Cavity or Hypopharynx, Eligible for chemoradiation

排除标准

  • •Inability to receive one of the treatment arms, laryngeal cancer, previous malignancies

研究者

发起方
ederlands Kanker Instituut

相似试验

进行中（未招募）
不适用
A four-arm randomized study comparing two different drugs as well as two different radiotherapy techniques
EUCTR2012-000437-39-NLederlands Kanker Instituut/Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)268
进行中（未招募）
不适用
Cetuximab and Cisplatin with or without Paclitaxel in recurrent/metastatic head and neck cancerRecurrent/metastatic head and neck squamous cell carcinomaMedDRA version: 14.1Level: LLTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2011-002564-24-ITISTITUTO NAZIONALE PER LA CURA TUMORI
进行中（未招募）
不适用
Cetuximab (ERBITUX) in combination with cisplatin or carboplatin and 5-fluorouracil in the first line treatment of subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck (''EXTREME'')
EUCTR2004-001667-22-ITMERCK S.P.A.
进行中（未招募）
不适用
Cetuximab (Erbitux) in combination with cisplatin or carboplatin and 5-fluorouracil in the first line treatment of subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck - EXTREMERecurrent and/or metastatic Squamous cell carcinoma of the head and neck (SCCHN)MedDRA version: 7.0Level: LLTClassification code 10025960
EUCTR2004-001667-22-CZMerck KGaA420
进行中（未招募）
不适用
Cetuximab (Erbitux) in combination with cisplatin or carboplatin and 5-fluorouracil in the first line treatment of subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck - EXTREMEMedDRA version: 7.0Level: LLTClassification code 10025960Recurrent and/or metastatic Squamous cell carcinoma of the head and neck (SCCHN)
EUCTR2004-001667-22-SEMerck KGaA420